Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.38 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | IL1B | P01584 | 1/20 | 0.34 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31341867 | 0.85 | CRBN (0.38) | IKZF2CRBNDDB1IKZF3IKZF1 | |
| SCHEMBL31342208 | 0.85 | CRBN (0.40) | IKZF2CRBNDDB1IKZF3TNF | |
| SCHEMBL31342024 | 0.83 | ADAM17 (0.38) | IKZF2CRBNDDB1IKZF3IKZF1 | |
| SCHEMBL31134471 | 0.81 | DDB1 (0.47) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL31342244 | 0.78 | MEN1 (0.37) | — | |
| SCHEMBL31134557 | 0.75 | DDB1 (0.50) | CRBNDDB1 | |
| SCHEMBL31134634 | 0.73 | HTR6 (0.45) | CRBNDDB1 | |
| SCHEMBL29094642 | 0.73 | IKZF2 (0.43) | IKZF2CRBNDDB1IKZF3TNF | |
| SCHEMBL30702784 | 0.73 | IKZF2 (0.43) | IKZF2CRBNDDB1IKZF3TNF | |
| SCHEMBL26067488 | 0.73 | CRBN (0.48) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | IKZF2 268/4885CRBN 207/4885DDB1 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.